With Sun Pharmaceutical's $4 billion buyout of Ranbaxy Laboratories all but wrapped up, the combined company has plenty on its plate: get plants banned by the FDA in order, get more products approved and to the market and find $250 million in savings with minimal layoffs.
Colorado's house of representatives passed a bill allowing pharmacists to substitute biosimilar versions of biotech drugs, even when the brands are prescribed by name. The approach would almost mirror the substitutions allowed with standard generic meds, except for the fact that pharmacists would be required to notify doctors about the change.
It's more bad news for Eli Lilly's Alimta in Europe. After losing a patent fight last year with Actavis in England, the Indianapolis drugmaker has now lost another in Germany, paving the way for knockoff versions of its top drug there.
SINGAPORE-- Aurobindo Pharma's U.S. unit, AuroMedics Pharma USA, says that if the U.S. FDA manages to speed up its approval process for generic drugs in the coming fiscal year, its earnings could shoot up by half.
Pharma analysts have different opinions on how much branded drugmakers will feel the heat from biosimilars--and when they'll feel it. But according to one Citi analyst, they're all underestimating the impact on AbbVie's top dog.
Good news for Teva when it comes to Mylan's generic version of AstraZeneca's Nexium: It won't be around for a little while.
SINGAPORE-- Pakistan's pharmaceutical industry reportedly has decided to step aside and cease opposition to a government plan to force down the price of certain drugs marketed in the country as of July 1, 2016.
SINGPAPORE-- Merck has confirmed it will move to let Simcere Pharmaceuticals run a high-profile China joint venture aimed at branded generic drugs announced in 2011 and focus instead on its mature products in the local market.
The U.S. FDA is hiring new inspectors in India to tackle the high rate of marketing applications made by local firms, an agency official said.
SINGAPORE-- India's government is getting into the generic drug business. The state reportedly will launch its own brand, "Jan Aushadhi," on July 1, planning to sell up to 504 drugs on its "essential" list in direct competition with commercial drugmakers.